
Photo: NDTV Profit
Business & Finance
Jubilant Pharmova Q2 Review: Nirmal Bang Raises Target Price, Bets On H2 Margin Recovery
TL;DR
- Nirmal Bang believes the FY28 ramp-up in Line 3, Line 4, and the PET network, together with SPECT normalisation, gives enough visibility for Jubilant Pharmova's stronger earnings.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Nov 17, 2026 · Updated 11/17/2026, 6:04:32 AM · Reported with: NDTV Profit
Sources (1)
NRI Bytes writes its own articles from the reporting below.
NDTV Profit — Jubilant Pharmova Q2 Review: Nirmal Bang Raises Target Price, Bets On H2 Margin RecoveryUp next · Business & Finance
FirstCry-parent Brainbees Solutions shares rally 13%: Q2 net loss narrows 75%, revenue jumps - Should you buy?
Read next →
More stories
Business & Finance
Meta tightens Instagram content recommendations in India amid govt scrutiny
37m ago
Business & Finance
Which are the top stocks to buy on November 17, 2026?
37m ago

Business & Finance
Paint Companies Announce Second Round Of November Price Hikes As Costs Rise | Profit Exclusive
1h ago

Business & Finance
Who Is Madison Huang? Meet Jensen Huang's Daughter, Her Nvidia Role And Equation With Interim CEO
1h ago


